Beigene Ltd (NASDAQ:BGNE) dropped 0.5% during mid-day trading on Monday . The company traded as low as $27.40 and last traded at $28.00, with a volume of 55,823 shares. The stock had previously closed at $28.15.

BGNE has been the topic of a number of analyst reports. Cowen and Company reiterated a “buy” rating on shares of Beigene in a research note on Thursday, May 12th. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Monday, May 16th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $39.67.

The company’s market cap is $951.88 million. The firm’s 50 day moving average price is $28.11 and its 200-day moving average price is $28.72.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. The firm earned $0.40 million during the quarter, compared to analysts’ expectations of $2.08 million. The company’s revenue was down 71.4% compared to the same quarter last year. Analysts anticipate that Beigene Ltd will post ($3.19) earnings per share for the current year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.